Kanda Junya, Brazauskas Ruta, Hu Zhen-Huan, Kuwatsuka Yachiyo, Nagafuji Koji, Kanamori Heiwa, Kanda Yoshinobu, Miyamura Koichi, Murata Makoto, Fukuda Takahiro, Sakamaki Hisashi, Kimura Fumihiko, Seo Sachiko, Aljurf Mahmoud, Yoshimi Ayami, Milone Giuseppe, Wood William A, Ustun Celalettin, Hashimi Shahrukh, Pasquini Marcelo, Bonfim Carmem, Dalal Jignesh, Hahn Theresa, Atsuta Yoshiko, Saber Wael
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Biol Blood Marrow Transplant. 2016 Apr;22(4):744-751. doi: 10.1016/j.bbmt.2015.12.027. Epub 2016 Jan 4.
The risk of acute graft-versus-host disease (GVHD) after HLA-matched sibling bone marrow transplantation (BMT) is lower in Japanese than in Caucasian patients. However, race may have differential effect on GVHD dependent on the graft source. North American Caucasian and Japanese patients receiving their first allogeneic BMT or peripheral blood stem cell transplantation from an HLA-matched sibling for leukemia were eligible. BMT was performed in 13% of the Caucasian patients and in 53% of the Japanese patients. On multivariate analysis, the interaction term between race and graft source was not significant in any of the models, indicating that graft source does not affect the impact of race on outcomes. The risk of grade III or IV acute GVHD was significantly lower in the Japanese patients compared with the Caucasian patients (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.57 to 0.96), which resulted in lower risk of nonrelapse mortality in the Japanese patients (HR, 0.69; 95% CI, 0.54 to 0.89). The risk of relapse was also lower in this group. The lower risks of nonrelapse mortality and relapse resulted in lower overall mortality rates among the Japanese patients. In conclusion, our data indicate that irrespective of graft source, the risk of severe acute GVHD is lower in Japanese patients, resulting in a lower risk of nonrelapse mortality.
在 HLA 配型相合的同胞骨髓移植(BMT)后,日本患者发生急性移植物抗宿主病(GVHD)的风险低于白种人患者。然而,种族对 GVHD 的影响可能因移植物来源而异。纳入符合条件的北美白种人和日本白血病患者,这些患者接受来自 HLA 配型相合同胞的首次异基因 BMT 或外周血干细胞移植。13%的白种人患者和 53%的日本患者接受了 BMT。多因素分析显示,种族与移植物来源之间的交互项在任何模型中均无显著性,这表明移植物来源不影响种族对结局的影响。与白种人患者相比,日本患者发生 III 级或 IV 级急性 GVHD 的风险显著降低(风险比[HR],0.74;95%置信区间[CI],0.57 至 0.96),这导致日本患者非复发死亡率较低(HR,0.69;95%CI,0.54 至 0.89)。该组患者的复发风险也较低。非复发死亡率和复发风险较低导致日本患者的总死亡率较低。总之,我们的数据表明,无论移植物来源如何,日本患者发生严重急性 GVHD 的风险较低,导致非复发死亡率较低。